Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.44 |
| ▸ | BTK | Q06187 | 1/20 | 0.43 |
| ▸ | HPGD | P15428 | 1/20 | 0.40 |
| ▸ | RECQL | P46063 | 1/20 | 0.38 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.37 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.37 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.37 |
| ▸ | STS | P08842 | 1/20 | 0.36 |
| ▸ | PTPN2 | P17706 | 1/20 | 0.35 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.35 |
| ▸ | PTPN6 | P29350 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26430589 | 0.87 | HSD17B10 (0.50) | HSD17B10SMN1; SMN2BTKHPGDRECQL | |
| SCHEMBL1439128 | 0.87 | HSD17B10 (0.50) | HSD17B10SMN1; SMN2BTKHPGDRECQL | |
| SCHEMBL581911 | 0.87 | LMNA (0.38) | HSD17B10SMN1; SMN2BTKHPGD | |
| SCHEMBL24047701 | 0.87 | HSD17B10 (0.50) | HSD17B10SMN1; SMN2BTKHPGDRECQL | |
| SCHEMBL29601341 | 0.86 | HSD17B10 (0.49) | HSD17B10SMN1; SMN2BTKHPGDRECQL | |
| SCHEMBL29785811 | 0.85 | HSD17B10 (0.48) | HSD17B10SMN1; SMN2BTKHPGDRECQL | |
| SCHEMBL16247244 | 0.84 | HSD17B10 (0.40) | HSD17B10SMN1; SMN2HPGDRECQLCHRM2 | |
| SCHEMBL5706909 | 0.83 | HSD17B10 (0.46) | HSD17B10SMN1; SMN2BTKHPGDRECQL | |
| SCHEMBL19642845 | 0.80 | HSD17B10 (0.60) | HSD17B10SMN1; SMN2BTKHPGDRECQL | |
| SCHEMBL21049842 | 0.80 | HSD17B10 (0.60) | HSD17B10SMN1; SMN2BTKHPGDRECQL |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3215505-B1 | PIPERIDINYLPYRAZOLOPYRIMIDINONES AND THEIR USE | Bayer Pharma AG (DE) | 2019-07-24 | — | — | EP | disclosed |
| US-10118930-B2 | Piperidinylpyrazolopyrimidinones and their use | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2018-11-06 | — | — | US | disclosed |
| US-20170334917-A1 | PIPERIDINYLPYRAZOLOPYRIMIDINONES AND THEIR USE | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2017-11-23 | — | — | US | disclosed |
| EP-3215505-A1 | PIPERIDINYLPYRAZOLOPYRIMIDINONES AND THEIR USE | Bayer Pharma Aktiengesellschaft (DE) | 2017-09-13 | — | — | EP | disclosed |
| WO-2016071216-A1 | PIPERIDINYLPYRAZOLOPYRIMIDINONES AND THEIR USE | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2016-05-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10118930-B2 | Piperidinylpyrazolopyrimidinones and their use | HAMP, SERPINC1, PRSS8 | HSD17B10 3305/4885SMN1; SMN2 3486/4885BTK 2824/4885 |
| US-20170334917-A1 | PIPERIDINYLPYRAZOLOPYRIMIDINONES AND THEIR USE | HAMP, SERPINC1, PRSS8 | HSD17B10 3305/4885SMN1; SMN2 3486/4885BTK 2824/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.